EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters

Arne Gessner, Jana Picurová, Lea Englhard, Fabian Müller, Martin F Fromm, Jörg König

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Arne Gessner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; FAU NeW - R…. Hauptthemen laut MEDLINE: Organic Cation Transport Proteins, Organic Cation Transporter 2, Kidney. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inhibition of renally expressed transport proteins such as organic cation transporter (OCT) 2 or multidrug and toxin extrusion protein (MATE) 1 can cause clinically relevant drug-drug interactions (DDIs). Endogenous biomarkers have been proposed as tools to characterize the DDI risk of new molecules in drug development. Many previously proposed biomarkers for OCT2/MATE1-mediated DDIs lack specificity and/or sensitivity indicating a need for additional, well characterized biomarkers. Recently, we demonstrated that treatment with cimetidine, a classical OCT/MATE-inhibitor, decreased the renal excretion of serotonin, tyramine, 1-methylhistamine, 5-amino valeric acid betaine, and 4-guanidinobutanoic acid in humans. So far, these compounds are incompletely characterized as substrates of OCT2, MATE1, and other drug transporters. We therefore used established cell models overexpressing OCT2 and/or MATE1, and cell models for other clinically important drug transporters (organic anion transporters 1 and 3, organic anion transporting polypeptides 1B1 and 1B3, and P-glycoprotein) to investigate the cellular uptake and/or vectorial transport of these 5 putative biomarkers. The in vitro results show that serotonin, tyramine, 1-methylhistamine, 5-amino valeric acid betaine, and 4-guanidinobutanoic acid are substrates of OCT2 and/or MATE1, supporting that the in vivo effect of cimetidine is due to inhibition of these transporters. Based on their transport by OCT2 and/or MATE1 compared to the minimal transport by other drug transporters and the in vivo effects of classical transport protein inhibitors in healthy volunteers, serotonin and 1-methylhistamine appear to be the most promising candidates for further validation as endogenous biomarkers for the early detection of clinically relevant OCT2- and MATE1-mediated renal DDIs. SIGNIFICANCE STATEMENT: This study characterizes 5 endogenous metabolites as substrates of the renally expressed transport proteins organic cation transporter (OCT) 2, multidrug and toxin extrusion protein (MATE) 1, and other important drug transporters. These transport proteins are known as important contributors to clinically observed drug-drug interactions. Of the respective 5 compounds, serotonin and 1-methylhistamine are the most promising candidates to be further investigated as biomarkers for interactions via OCT2/MATE1, which could improve drug-drug interaction assessment during clinical drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Organic Cation Transport ProteinsOrganic Cation Transporter 2KidneyHumansBiomarkersDrug InteractionsHEK293 CellsCimetidineBiological TransportMale

Stichwörter der Autor:innen

BiomarkerDrug-drug interactionMATE1OCT2Renal drug excretionTransport proteins

Substanzen

Organic Cation Transport ProteinsOrganic Cation Transporter 2BiomarkersSLC47A1 protein, humanCimetidineSLC22A2 protein, human

Autor:innen und Institutionen

  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; FAU NeW - Research Center New Bioactive Compounds, Friedrich-Alexander-Universitä…
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Zitieren

APA

Gessner, A., Picurová, J., Englhard, L., Müller, F., Fromm, M. F., & König, J. (2025). Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100155

Vancouver

Gessner A, Picurová J, Englhard L, Müller F, Fromm MF, König J. Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100155

BibTeX
@article{Gessner2025,
  author = {Gessner, Arne and Picurová, Jana and Englhard, Lea and Müller, Fabian and Fromm, Martin F and König, Jörg},
  title = {Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100155}
}
Kostenlos starten →